Vident Investment Advisory
ARCT icon

Vident Investment Advisory’s Arcturus Therapeutics ARCT Stock Holding History

Vident Investment Advisory’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,205
Closed -$210K – 1158
2021
Q2 		$210K Buy
+6,205
New +$210K 0.01% 1040

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

Vident Investment Advisory's ARCT Position: Q3 2021 in Review

Vident Investment Advisory sold out of Arcturus Therapeutics (ARCT) in Q3 2021, closing a stake of 6,205 shares — an estimated $210K sold.

Vident Investment Advisory first reported a position in ARCT in Q2 2021 and held it in 1 quarter. The position peaked at $210K in Q2 2021. 156 funds tracked by Wall St. Rank hold ARCT as of Q3 2021.

  • Vident Investment Advisory reported no remaining Arcturus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 6,205 Arcturus Therapeutics shares in Q3 2021, an estimated $210K.
  • Vident Investment Advisory first reported a position in Arcturus Therapeutics in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's Arcturus Therapeutics position peaked at $210K in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.